42%的在线药店提供西马格鲁蒂德(Wegovy的主要成份),根据JAMA网络公开研究,在没有有效许可证的情况下经营,在没有处方的情况下销售药品。 42% of online pharmacies offering semaglutide, a key ingredient in Wegovy, operate without valid licenses and sell drugs without prescriptions, per a JAMA Network Open study.
JAMA Network Open的一项研究显示，提供索马鲁肽（诺和诺德抗肥胖药物Wegovy的关键成分）的在线药店中有42%在没有有效许可证的情况下经营，并在没有处方的情况下销售药物。 42% of online pharmacies offering semaglutide, a key ingredient in Novo Nordisk's anti-obesity drug Wegovy, operate without valid licenses and sell drugs without prescriptions, a JAMA Network Open study reveals. 从这些未经授权的来源购买的假冒减重药品使病人面临获得不安全和无效产品的风险,这些产品含有低纯度的硫酸盐、过量剂量,有时还含有细菌污染。 Counterfeit weight loss drugs purchased from these unauthorized sources expose patients to risks of receiving unsafe and ineffective products, containing low-purity semaglutide, excessive dosages, and in some cases, bacterial contamination. 这项研究强调,由于价格高、保险覆盖面不足和药物短缺,从未经授权的来源获得这些药物的风险很大。 The study highlights the risks associated with obtaining these drugs from unauthorized sources due to high prices, lack of insurance coverage, and drug shortages.